Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Total Non-Current Liabilities (2020 - 2022)

Historic Total Non-Current Liabilities for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to $18.2 million.

  • Atea Pharmaceuticals' Total Non-Current Liabilities changed N/A to $18.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $18.2 million, marking a year-over-year change of. This contributed to the annual value of $56.9 million for FY2021, which is 8198.74% down from last year.
  • Latest data reveals that Atea Pharmaceuticals reported Total Non-Current Liabilities of $18.2 million as of Q3 2022.
  • Atea Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $315.8 million for Q4 2020, and its period low was $10.8 million during Q3 2020.
  • In the last 3 years, Atea Pharmaceuticals' Total Non-Current Liabilities had a median value of $44.1 million in 2021 and averaged $123.6 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first tumbled by 8198.74% in 2021, then tumbled by 8981.45% in 2022.
  • Over the past 3 years, Atea Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $315.8 million in 2020, then tumbled by 81.99% to $56.9 million in 2021, then plummeted by 67.97% to $18.2 million in 2022.
  • Its Total Non-Current Liabilities stands at $18.2 million for Q3 2022, versus $27.9 million for Q2 2022 and $31.4 million for Q1 2022.